SCHEMBL281598

SCHEMBL281598

CNC(=O)c1cc(Cl)c(C)[nH]1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.50
KMT2A Q03164 1/20 0.45
KCNA6 P17658 1/20 0.45
KCNA3 P22001 1/20 0.45
KCNA4 P22459 1/20 0.45
DOT1L Q8TEK3 1/20 0.43
CREBBP Q92793 2/20 0.42
NPC1 O15118 1/20 0.41
PTPN11 Q06124 1/20 0.40
NUDT1 P36639 2/20 0.39
BRD4 O60885 2/20 0.38
BRPF1 P55201 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
CHEK1 O14757 1/20 0.37
RET P07949 1/20 0.37
PDGFRB P09619 1/20 0.37
PIM1 P11309 1/20 0.37
PDGFRA P16234 1/20 0.37
GSK3B P49841 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24112866 0.82 ALOX15 (0.51) ALOX15KMT2AKCNA6KCNA3KCNA4
SCHEMBL24113377 0.80 ALOX15 (0.45) ALOX15KMT2ADOT1LCREBBPNPC1
SCHEMBL508616 0.78 GRIN1 (0.47) ALOX15KMT2AALDH1A1HPGD
SCHEMBL20645712 0.77 CYP1A2 (0.50) KCNA6KCNA3KCNA4
SCHEMBL13070795 0.76 CCNC (0.49) KMT2AKCNA6KCNA3KCNA4NUDT1
SCHEMBL26323206 0.76 BRD4 (0.44) ALOX15KMT2ACREBBPNPC1PTPN11
SCHEMBL13488601 0.74 KMT2A (0.72) ALOX15KMT2ADOT1LNPC1ALDH1A1
SCHEMBL19173476 0.73 ALOX15 (0.40) ALOX15KMT2ADOT1LCREBBPNPC1
SCHEMBL18510263 0.70 GRIN1 (0.66) ALOX15KMT2ANUDT1HPGD
SCHEMBL507897 0.70 ALOX15 (0.55) ALOX15KMT2ANPC1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957087-B2 Heterocyclic substituted acardite derivate and application thereof Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) 2015-02-17 US disclosed
EP-2428506-B1 HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF NANJING LUYESIKE PHARMACEUTICAL CO LTD (CN) 2014-03-05 EP disclosed
EP-2428506-A1 HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF Jiangsu Provincial Institute Of Materia Medica Co. (CN) 2012-03-14 EP disclosed
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 ALOX15 3775/4885KMT2A 1811/4885KCNA6 3317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.